Michael Davidson

Chief Executive Officer chez FRAZIER LIFESCIENCES ACQUISITION CORPORATION Fortune : 13 045 $ au 31/03/2024

Profil

Michael H.
Davidson founded Omthera Pharmaceuticals, Inc. in 2008, where he worked as Chief Medical Officer from 2008 to 2013, Chicago Center for Clinical Research in 1987, where he worked as President & Chief Executive Officer from 1987 to 2008, Corvidia Therapeutics, Inc. in 2016, where he worked as Co-Chief Scientific & Medical Officer from 2018 to 2020, and Trofi Nutritionals, Inc. in 2021, where he is working as Chief Scientific Officer from 2021.
Dr. Davidson also founded SonoThera, Inc., where he is working as Chairman.
Dr. Davidson also currently works at NewAmsterdam Pharma BV, as Chief Executive Officer & Executive Director from 2020, NewAmsterdam Pharma Holding BV, as Chief Executive Officer & Executive Director from 2020, NewAmsterdam Pharma Co. NV, as President, Chief Executive Officer & Director from 2023, Tenax Therapeutics, Inc., as Independent Director from 2021, Sonogene LLC, as Director, Silence Therapeutics Plc, as Non-Executive Director from 2021, The University of Chicago, as Director-Lipid Clinic & Professor, Preventive Cardiology Institute, Inc., as Director, Abcentra, Inc., as Director from 2021, Midwest Lipid Association, as Director, Inositec AG, as Director from 2020, Jocasta Neuroscience, Inc., as Director, NanoPhoria Srl, as Director, American College of Chest Physicians, as Member, American College of Cardiology Foundation, as Member, and The University of Chicago Department of Medicine, as Professor from 2007.
Dr. Davidson also formerly worked at ABIONYX Pharma SA, as Independent Director from 2015 to 2019, Caladrius Biosciences, Inc., as Independent Director, Cerenis Therapeutics, Inc., as Director from 2015 to 2019, and National Lipid Association, as President from 2010 to 2011.
Dr. Davidson received his undergraduate degree from Northwestern University and doctorate degree from The Ohio State University.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
SILENCE THERAPEUTICS PLC 0,01%	01/03/2024	12 993 ( 0,01% )	11 434 $	31/07/2023
TENAX THERAPEUTICS, INC. 0,02%	20/03/2024	380 ( 0,02% )	1 611 $	31/03/2024
NEWAMSTERDAM PHARMA COMPANY N.V. -.--%	01/01/2024	0 ( -.--% )	- $	31/03/2024

Postes actifs de Michael Davidson

Sociétés	Poste	Début
SILENCE THERAPEUTICS PLC	Director/Board Member	06/01/2021
TENAX THERAPEUTICS, INC.	Director/Board Member	25/02/2021
FRAZIER LIFESCIENCES ACQUISITION CORPORATION	Chief Executive Officer	01/11/2022
Sonogene LLC	Director/Board Member	-
NanoPhoria Srl	Director/Board Member	-
SonoThera, Inc.	Founder	-
NewAmsterdam Pharma BV	Chief Executive Officer	01/08/2020
Jocasta Neuroscience, Inc.	Director/Board Member	-
The University of Chicago	Corporate Officer/Principal	-
░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░ ░░░░░░	░░░░░░░░░░
░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ ░░	░░░░░ ░░░░░░░░░ ░░░░░░░	░░░░░░░░░░

Anciens postes connus de Michael Davidson

Sociétés	Poste	Fin
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░	░░░░░ ░░░░░░░░░ ░░░░░░░	░░░░░░░░░░
░░░░░░░ ░░░░░░	░░░░░░░░░░░░░░ ░░░░░░	░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░ ░░░░░░	░░░░░░░░░░
░░░░░░░░ ░░░░░ ░░░░░░░░░░░	░░░░░░░░░	░░░░░░░░░░
░░░░░░░ ░░░░░░ ░░░ ░░░░░░░░ ░░░░░░░░	░░░░░ ░░░░░░░░░ ░░░░░░░	░░░░░░░░░░

Formation de Michael Davidson

Northwestern University	Undergraduate Degree
The Ohio State University	Doctorate Degree